What to know about PCOS & insulin resistance
Polycystic ovary syndrome is a hormonal disorder that affects the ovaries and much of the body, and the 2023 international guideline puts it at 10% to 13% of reproductive-age women worldwide. The MedlinePlus polycystic ovary syndrome page says most people with it have at least two of three problems: not ovulating, high androgen levels and growths on the ovaries. It now lists a second name, polyendocrine metabolic ovary syndrome (PMOS).
PCOS and insulin resistance are closely tied, and NICHD reports that more than half of women with PCOS have insulin resistance. It means your body cannot use insulin properly, and MedlinePlus lists it among the factors behind PCOS. International guideline authors call it a pathophysiological factor in the condition. Regardless of age or BMI, women with PCOS also have a higher risk of impaired glucose tolerance and type 2 diabetes.
MedlinePlus lists weight gain and trouble losing weight among PCOS symptoms. It is not a dead end. With structured support, weight management appears to work as well in PCOS as in the general population, according to the guideline, and NICHD notes that losing weight can improve both insulin and cholesterol levels.
GLP-1 medicines entered the PCOS conversation because they act on appetite and blood sugar. Arbor's review of liraglutide research in PCOS covers the trial evidence for an older GLP-1. This guide covers the practical steps and where semaglutide fits.
How to lose weight with PCOS step by step
If you are working out how to lose weight with PCOS, order matters more than any single tactic. These five steps follow the 2023 guideline, which puts lifestyle change first and treats medicine as an addition, not a replacement.
- 01
Step 1: Get a diagnosis & baseline labs
In adults, a PCOS diagnosis rests on at least two of three features: irregular cycles, signs or lab evidence of high androgens, and polycystic ovaries on ultrasound or a high AMH blood level. Thyroid and prolactin problems are among the causes ruled out first. Ask for baseline labs at diagnosis. Every adult with PCOS should have glucose status checked, with the 75-gram oral glucose tolerance test as the most accurate option, plus a lipid panel at any weight. Standard insulin tests are not recommended for routine care.
These numbers are your starting line.
- 02
Step 2: Build a PCOS diet around protein & fiber
No single PCOS diet has proven advantages. Guideline reviewers found no evidence that any one diet composition beats another and recommend healthy eating you can sustain, with a tailored calorie deficit when weight loss is the goal. MedlinePlus says fiber makes you feel full faster and advises adults to eat 21 to 38 grams a day. Protein should supply 10% to 35% of your calories, and an ounce of most protein-rich foods holds about 7 grams. On a GLP-1 you may eat less overall, and the guide to protein targets on GLP-1 treatment covers the numbers.
Pick meals you can repeat on a busy week.
- 03
Step 3: Add strength training
The guideline's activity targets for adults are 150 to 300 minutes a week of moderate activity, or 75 to 150 minutes of vigorous activity, plus muscle-strengthening work on two non-consecutive days. For modest weight loss and preventing regain, that floor rises to 250 minutes of moderate activity. Body-weight moves, resistance bands and free weights all work. Start light and build gradually.
A healthy lifestyle brings benefits even when the scale does not move, the guideline notes.
- 04
Step 4: Ask whether semaglutide for PCOS fits you
Semaglutide for PCOS is an off-label conversation, because no semaglutide product is FDA approved for PCOS. Under the guideline, GLP-1 medicines such as semaglutide could be considered alongside lifestyle change to manage higher weight in adults with PCOS, following general population rules. A 2026 evidence review still calls the semaglutide data in PCOS sparse. Your clinician checks eligibility first: your health history, other medicines, any personal or family history of medullary thyroid carcinoma or MEN 2, and whether you are pregnant or planning a pregnancy. If you are weighing tirzepatide instead, the companion guide on tirzepatide, PCOS & fertility covers its birth control and pregnancy-planning questions.
Bring your labs and cycle history. The decision rests on them.
- 05
Step 5: Track progress beyond the scale
Weight is one number among several. Waist circumference, waist-to-hip ratio and metabolic health count too, and glucose status should be rechecked every one to three years, or as your clinician advises. Self-monitoring is a recommended behavioral strategy. Once a month, log your weight, waist, strength sessions and cycle dates, and share the trend with your clinician rather than judging any single week.
PCOS weight gain mistakes to avoid
PCOS weight gain is not a personal failing, and many women with PCOS face weight stigma in health care, as the guideline acknowledges. A few patterns slow progress most.
- Following a strict PCOS diet you cannot keep. Unduly restrictive, unbalanced eating is what the guideline warns against.
- Skipping the labs. Without a baseline, you cannot tell whether your metabolic health is improving.
- Relying on supplements. Inositol showed limited benefits for weight in the guideline review, and supplements are regulated differently from prescription medicines.
- Stacking GLP-1 products. The Wegovy label does not recommend using semaglutide with other semaglutide products or with any other GLP-1 medicine.
- Judging progress by the scale alone. A smaller waist and better metabolic health are gains in their own right.
- Stopping a GLP-1 without a plan. The guideline notes a high risk of weight regain after these medicines stop, so plan any change with your clinician.
- Waiting to mention pregnancy plans. They change whether semaglutide is right for you, so raise them at the first visit.
Eligibility comes first
Under the Wegovy label, semaglutide is not used with a personal or family history of medullary thyroid carcinoma or MEN 2, or after a serious allergic reaction to it. For weight reduction, the label says to stop it when pregnancy is recognized and at least 2 months before a planned pregnancy, and the PCOS guideline calls for effective contraception whenever pregnancy is possible on a GLP-1. Your clinician checks these before any prescription. For anything else, message your Arbor clinician.
Semaglutide shots with Arbor
Searches for Ozempic for PCOS and Wegovy PCOS lead to the same molecule and the same approval answer. Ozempic is approved for adults with type 2 diabetes. Wegovy is approved to reduce excess weight and keep it off in certain adults and children 12 and older, to lower heart risk in certain adults and to treat a liver condition called MASH. Neither label lists PCOS. A clinician can still consider semaglutide for higher weight when you qualify, the use the PCOS guideline describes.
Arbor semaglutide shots are compounded semaglutide, injected once a week at home. Compounded semaglutide is not FDA approved, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. A board-certified physician reviews your health history and decides whether treatment is appropriate. If it is not the right fit, you are not charged.
Arbor's program is built for adults typically at a BMI of 27 or higher. Licensed clinicians are available around the clock, the medication is compounded by licensed U.S. pharmacies, and registered-dietitian aftercare follows the program. Pricing starts at $99 and stays flat as your dose rises, though it can vary by plan and offer. Your clinician sets your dose and schedule.
Frequently asked questions
Yes, if your clinician agrees. Metformin for PCOS is off-label, since NICHD notes it is not FDA approved for the condition, but the guideline says it should be considered in adults with a BMI of 25 or more. A small, single-center, open-label 2025 trial in China randomized 100 women with PCOS and higher weight, and 80 completed it. Those on metformin plus semaglutide, stepped up to 1 mg weekly, lost an average of 6.09 kg over 16 weeks, against 2.25 kg on metformin alone. That is below the 2.4 mg Wegovy maintenance dose, and the paper does not name the semaglutide product used.
Early evidence points that way, though searches for "GLP 1 for PCOS" turn up stronger claims than the studies support. A 2026 scoping review of 25 semaglutide studies in PCOS reported improvements in fasting insulin and HOMA-IR, a common insulin resistance score. Most of those studies were small or observational, and many were reviewed only from abstracts or conference summaries. No GLP-1 for PCOS is FDA approved, and the guideline does not recommend routine insulin tests, so your clinician follows glucose and lipids instead.
There is no fixed timeline. On the Wegovy injection label, the dose steps up every four weeks and reaches maintenance at week 17, so the first months are a build-up. The same 2026 scoping review put average losses at 7.6 to 11.5 kg over three to six months, drawn mostly from small or observational studies. Those figures describe the products and doses those studies used, not compounded semaglutide, which is not FDA approved. PCOS weight loss varies from person to person. The month-by-month look at realistic semaglutide results walks through the first year.
Sources
- Polycystic Ovary Syndrome. MedlinePlus, U.S. National Library of Medicine.
- Teede HJ et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469.
- What are the treatments for PCOS? Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Polycystic Ovary Syndrome (PCOS) fact sheet. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- WEGOVY (semaglutide) injection and tablets, prescribing information, revised June 2026. DailyMed, U.S. National Library of Medicine.
- OZEMPIC (semaglutide) injection, prescribing information, revised May 2026. DailyMed, U.S. National Library of Medicine.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration.
- Chen H et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome. Reprod Biol Endocrinol. 2025;23:108.
- La Vignera S, Condorelli RA. Efficacy and Safety of Semaglutide in Patients with Polycystic Ovary Syndrome: A Scoping Review. Biomedicines. 2026;14(8):1845.
- Jensterle M, Janez A. Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map. Drugs. 2026;86(7):1013-1032.
- Dietary fiber. MedlinePlus Medical Encyclopedia.
- Protein in diet. MedlinePlus Medical Encyclopedia.
Keep reading
All 179 articles →
SemaglutideSemaglutide Shots vs Foundayo: A Weekly Injection or a Daily Pill
Semaglutide is a weekly injection with years of trial data behind it. Foundayo is a daily GLP-1 pill approved in April 2026. Here is the honest comparison, point by point.
By Arbor Health Team
SemaglutideSemaglutide dosage chart in units for injectable semaglutide
Your dose is written in milligrams, your syringe is marked in units, and the concentration on your vial connects the two. Here is how to read a dosage chart against your own label.
By Arbor Health Team
SemaglutideHow to Inject Semaglutide at Home: Injection Sites, Steps & Rotation
A once-weekly semaglutide injection goes under the skin of your stomach, thigh or upper arm, once a week on the same day. Here is how to inject semaglutide from a compounded vial the way FDA and NIH guidance describe it, with your dose always set by your clinician.
By Arbor Health Team




